The Role of the CD38 Receptor in the Progression of HIV

April 24, 2019 | 216 views

CD38, or cyclic ADP ribose hydrolase, is a glycoprotein found on the surface of many immune cells. Binding of CD38 to its target ligand results in T cell co-stimulation, B cell maturation, and induction of cytokine production by several cell types. HIV infection is characterized by the depletion of CD4+ T cells, leading to a hyperactive immune system. The depletion of CD4+ T cells has long been correlated with the overexpression of the cell surface adhesion receptor protein, CD38.

Spotlight

STATinMED Research

Since 2007, STATinMED Research has helped life science companies discover data, develop insights, and deliver optimal solutions to realize maximum value.

OTHER ARTICLES
BUSINESS INSIGHTS

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | June 30, 2022

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More
PHARMA TECH

What are the advantages of PCD Pharma Company?

Article | October 6, 2022

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More
PHARMA TECH

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | July 13, 2022

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Spotlight

STATinMED Research

Since 2007, STATinMED Research has helped life science companies discover data, develop insights, and deliver optimal solutions to realize maximum value.

Related News

ViiV to develop bNAb candidate to treat and prevent HIV

Pharmaceutical Technology | November 22, 2019

ViiV Healthcare has agreed to develop an investigational broadly neutralising antibody (bNAb) N6LS to treat and prevent human immunodeficiency virus 1 (HIV-1) infection. Founded in 2009 by GlaxoSmithKline (GSK) and Pfizer, ViiV focuses on developing therapies against HIV. Japanese pharmaceutical firm Shionogi also holds a stake in ViiV. The development of the bNAb candidate falls under an exclusive licensing agreement between GSK and the National Institutes of Health (NIH)’s National Institute of Allergy and Infectious Diseases (NIAID). N6LS binds to the gp120 site on the surface of the virus and prevents its entry into healthy CD4+ T-cells, a type of immune system cells. The process is meant to stop HIV replication and potentially prevent HIV transmission. NIAID’s Laboratory of Immunoregulation and Vaccine Research Center (VRC) researchers discovered and conducted initial development of N6LS.

Read More

Better HIV, lupus and hep C treatments possible with malaria discovery

Drug Target Review | November 20, 2019

In laboratory models, a research team has showed that strong inflammatory signals caused by malaria infection activate molecules that trigger the production of highly potent antibodies to fight the disease. The same inflammatory signals are seen in human malaria infections, chronic viral infections and autoimmune disorders. This suggests the discovery could be harnessed to develop new vaccines and therapies that are better able to fight infections such as hepatitis C and HIV as well as treat diseases such as lupus. The research was led by PhD student Ms Ann Ly and Dr Diana Hansen from the Walter and Eliza Hall Institute, Australia, with collaborators Dr Yiang Liao and Associate Professor Wei Shi and Professor Axel Kallies from the Doherty Institute. “When we began this study, we expected to see that inflammation was also having a negative effect on B cells. In fact, we found the opposite was true. The inflammatory signals were improving the quality of the antibodies produced, by sending B cells to an elite training ground, where they underwent an exhaustive program to become ‘professional predators’.”

Read More

Gilead demonstrates non-inferiority of Descovy to Truvada for HIV PrEP

Pharmaceutical Technology | November 07, 2019

Gilead Sciences has published data from the Phase III 96-week DISCOVER trial in which Descovy (emtricitabine 200mg and tenofovir alafenamide 25mg) demonstrated non-inferiority to another Gilead drug Truvada (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg) for pre-exposure prophylaxis (PrEP). The DISCOVER study only evaluated men and transgender women who have sex with men and are at risk of sexually acquiring human immunodeficiency virus (HIV) infection. Descovy is currently only approved for at-risk adults and adolescents at risk of sexually acquired HIV-1 infection, except individuals at risk from vaginal sex, because the drug is yet to be evaluated for efficacy in this patient population. Gilead has committed itself to carrying out clinical trials of Descovy in cisgender women and adolescent females at risk of sexually transmitted HIV-1 infection in Africa. Results from the DISCOVER trial showed that eight of the 2,670 people in the Descovy group experienced an incident of HIV infection, compared to 15 of the 2,665 participants in the Truvada group.

Read More

ViiV to develop bNAb candidate to treat and prevent HIV

Pharmaceutical Technology | November 22, 2019

ViiV Healthcare has agreed to develop an investigational broadly neutralising antibody (bNAb) N6LS to treat and prevent human immunodeficiency virus 1 (HIV-1) infection. Founded in 2009 by GlaxoSmithKline (GSK) and Pfizer, ViiV focuses on developing therapies against HIV. Japanese pharmaceutical firm Shionogi also holds a stake in ViiV. The development of the bNAb candidate falls under an exclusive licensing agreement between GSK and the National Institutes of Health (NIH)’s National Institute of Allergy and Infectious Diseases (NIAID). N6LS binds to the gp120 site on the surface of the virus and prevents its entry into healthy CD4+ T-cells, a type of immune system cells. The process is meant to stop HIV replication and potentially prevent HIV transmission. NIAID’s Laboratory of Immunoregulation and Vaccine Research Center (VRC) researchers discovered and conducted initial development of N6LS.

Read More

Better HIV, lupus and hep C treatments possible with malaria discovery

Drug Target Review | November 20, 2019

In laboratory models, a research team has showed that strong inflammatory signals caused by malaria infection activate molecules that trigger the production of highly potent antibodies to fight the disease. The same inflammatory signals are seen in human malaria infections, chronic viral infections and autoimmune disorders. This suggests the discovery could be harnessed to develop new vaccines and therapies that are better able to fight infections such as hepatitis C and HIV as well as treat diseases such as lupus. The research was led by PhD student Ms Ann Ly and Dr Diana Hansen from the Walter and Eliza Hall Institute, Australia, with collaborators Dr Yiang Liao and Associate Professor Wei Shi and Professor Axel Kallies from the Doherty Institute. “When we began this study, we expected to see that inflammation was also having a negative effect on B cells. In fact, we found the opposite was true. The inflammatory signals were improving the quality of the antibodies produced, by sending B cells to an elite training ground, where they underwent an exhaustive program to become ‘professional predators’.”

Read More

Gilead demonstrates non-inferiority of Descovy to Truvada for HIV PrEP

Pharmaceutical Technology | November 07, 2019

Gilead Sciences has published data from the Phase III 96-week DISCOVER trial in which Descovy (emtricitabine 200mg and tenofovir alafenamide 25mg) demonstrated non-inferiority to another Gilead drug Truvada (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg) for pre-exposure prophylaxis (PrEP). The DISCOVER study only evaluated men and transgender women who have sex with men and are at risk of sexually acquiring human immunodeficiency virus (HIV) infection. Descovy is currently only approved for at-risk adults and adolescents at risk of sexually acquired HIV-1 infection, except individuals at risk from vaginal sex, because the drug is yet to be evaluated for efficacy in this patient population. Gilead has committed itself to carrying out clinical trials of Descovy in cisgender women and adolescent females at risk of sexually transmitted HIV-1 infection in Africa. Results from the DISCOVER trial showed that eight of the 2,670 people in the Descovy group experienced an incident of HIV infection, compared to 15 of the 2,665 participants in the Truvada group.

Read More

Events